Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE

Keyphrases

• Disease Pattern 100%
• Patient Characteristics 100%
• Pulmonary Arterial Hypertension 100%
• Selexipag 100%
• World Health Organization Functional Class 25%
• United States 16%
• Twice Daily 16%
• Intermediate Risk 16%
• State-based 16%
• Adverse Effects 8%
• High Risk 8%
• Patient-completed 8%
• Working Diagnosis 8%
• Adverse Events 8%
• Monotherapy 8%
• Clinical Characteristics 8%
• Connective Tissue Disease 8%
• Clinic Visits 8%
• Disease-associated 8%
• Serious Adverse Events 8%
• Titration 8%
• Hypertension Management 8%
• Risk Score 8%
• Endothelin Receptor Antagonist 8%
• World Health Organization 8%
• 1-year Mortality 8%
• Specific Treatment 8%
• Routine Clinical Practice 8%
• Dose Titration 8%
• Multicenter Observational Study 8%
• Real-world Clinical Practice 8%
• Combination Regimen 8%
• Maintenance Dose 8%
• Drug Registry 8%
• Double Therapy 8%
• Pulmonary Arterial Hypertension-targeted Therapy 8%
• Prostacyclin Receptor Agonist 8%
• Phosphodiesterase Type V Inhibitors 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Pulmonary Hypertension 100%
• Selexipag 100%
• Diseases 100%
• Adverse Event 16%
• Monotherapy 8%
• Connective Tissue Disease 8%
• Receptor Agonist 8%
• Observational Study 8%
• Phosphodiesterase V Inhibitor 8%
• Endothelin Receptor Antagonist 8%
• Maintenance Dose 8%
• Prostacyclin Receptor 8%